RightFit Trial Directory

Lung Cancer clinical trials in Houston, TX

113 recruiting lung cancer studies with a site in Houston, TX.

All trials in Houston, TX · All Lung Cancer trials

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

Dallas, TX · Houston, TX · +37 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Abilene, TX · Amarillo, TX · Austin, TX · +1147 more sites

RecruitingPhase 1 / Phase 2NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Sponsor: Revolution Medicines, Inc.

Houston, TX · Irving, TX · +27 more sites

RecruitingPhase 1NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Sponsor: Eli Lilly and Company

Houston, TX · San Antonio, TX · +21 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Dallas, TX · Houston, TX · +51 more sites

RecruitingPhase 1 / Phase 2NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Sponsor: Tango Therapeutics, Inc.

Houston, TX · +14 more sites

RecruitingPhase 1 / Phase 2NCT07038343

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Sponsor: Avenzo Therapeutics, Inc.

Dallas, TX · Houston, TX · San Antonio, TX · +16 more sites

RecruitingPhase 1NCT06545331

Study of XB010 in Subjects With Solid Tumors

Sponsor: Exelixis

Austin, TX · Dallas, TX · Houston, TX · +13 more sites

RecruitingPhase 2 / Phase 3NCT06712316

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Sponsor: BioNTech SE

Houston, TX · +52 more sites

RecruitingPhase 1 / Phase 2NCT07020221

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Sponsor: Verastem, Inc.

Houston, TX · +12 more sites

RecruitingPhase 3NCT06712355

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Sponsor: BioNTech SE

Houston, TX · Sugar Land, TX · +33 more sites

RecruitingPhase 1NCT07462377

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Sponsor: EpiBiologics

Houston, TX · San Antonio, TX · +4 more sites

RecruitingPhase 1 / Phase 2NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier

Houston, TX · San Antonio, TX · +19 more sites

RecruitingPhase 3NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Abilene, TX · Allen, TX · Amarillo, TX · +238 more sites

RecruitingPhase 2NCT07415005

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase not listedNCT06840288

Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT07070232

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Sponsor: BioNTech SE

Houston, TX · San Antonio, TX · +17 more sites

RecruitingPhase 2 / Phase 3NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Sponsor: Bristol-Myers Squibb

Houston, TX · San Antonio, TX · +26 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Abilene, TX · Allen, TX · Amarillo, TX · +223 more sites

RecruitingPhase not listedNCT04474301

Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingNot applicableNCT04783168

Walking After Surgery to Improve Recovery and Outcomes After Surgery, AIRTECH Study

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Austin, TX · Fort Bliss, TX · Houston, TX · +84 more sites

RecruitingPhase 2NCT05967689

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Sponsor: Taiho Oncology, Inc.

Houston, TX · +17 more sites

RecruitingPhase 3NCT06216301

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Sponsor: NovoCure GmbH

Dallas, TX · Edinburg, TX · +35 more sites

RecruitingPhase not listedNCT07220096

Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT07492680

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Sponsor: Bristol-Myers Squibb

Houston, TX · +15 more sites

RecruitingPhase 1 / Phase 2NCT05797168

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Sponsor: AstraZeneca

Houston, TX · +12 more sites

RecruitingPhase 1 / Phase 2NCT06060613

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Sponsor: Obsidian Therapeutics, Inc.

Houston, TX · +8 more sites

RecruitingPhase 2 / Phase 3NCT07005102

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Sponsor: AbbVie

Austin, TX · Houston, TX · Palestine, TX · +15 more sites

RecruitingPhase 1NCT07164313

A Study of ZW251 in Participants With Advanced Solid Tumors

Sponsor: Zymeworks BC Inc.

Houston, TX · San Antonio, TX · +6 more sites

RecruitingPhase 1NCT06270706

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Sponsor: Pliant Therapeutics, Inc.

Austin, TX · Fort Worth, TX · Houston, TX · +13 more sites

RecruitingPhase 2NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: Daiichi Sankyo

Houston, TX · +12 more sites

RecruitingPhase 1 / Phase 2NCT07189871

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Sponsor: Radiopharm Theranostics, Ltd

Houston, TX · +4 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

Amarillo, TX · Austin, TX · Denton, TX · +35 more sites

RecruitingPhase 3NCT07361510

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Sponsor: Bristol-Myers Squibb

Galveston, TX · Houston, TX · San Antonio, TX · +38 more sites

RecruitingPhase 1NCT05877599

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Sponsor: AstraZeneca

Houston, TX · Round Rock, TX · +18 more sites

RecruitingPhase 1NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Sponsor: IDEAYA Biosciences

Fort Worth, TX · Houston, TX · +20 more sites

RecruitingPhase 1NCT06218914

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Sponsor: AstraZeneca

Dallas, TX · Galveston, TX · Houston, TX · +15 more sites

RecruitingNot applicableNCT06919874

Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1 / Phase 2NCT07579221

Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 3NCT06357533

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Sponsor: AstraZeneca

Fort Worth, TX · Houston, TX · +60 more sites

RecruitingPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Sponsor: Bristol-Myers Squibb

Abilene, TX · Harlingen, TX · Houston, TX · +53 more sites

RecruitingPhase 2 / Phase 3NCT07063745

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Sponsor: Bristol-Myers Squibb

Dallas, TX · El Paso, TX · Houston, TX · +41 more sites

RecruitingPhase not listedNCT07174388

An External Control Arm Study in Non-Small Cell Lung Cancer

Sponsor: N-Power Medicine

Houston, TX · +10 more sites

RecruitingPhase 1 / Phase 2NCT07488676

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Sponsor: Astellas Pharma Global Development, Inc.

Austin, TX · Houston, TX · Irving, TX · +15 more sites

RecruitingPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sponsor: SystImmune Inc.

Houston, TX · +20 more sites

RecruitingPhase 1 / Phase 2NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Sponsor: Blueprint Medicines Corporation

Houston, TX · +9 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Abilene, TX · Austin, TX · Dallas, TX · +94 more sites

RecruitingPhase 1 / Phase 2NCT07224152

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 1NCT07617337

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Sponsor: Chugai Pharmaceutical

Houston, TX

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.